Filtered By:
Condition: Bleeding
Countries: Spain Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 72 results found since Jan 2013.
Effectiveness and safety of oral anticoagulants for non-valvular atrial fibrillation: a population-based cohort study in primary healthcare in Catalonia
Conclusion: Being men, a previous event and DOAC-switch posed a higher risk for all study outcomes. direct oral anticoagulants had a protective effect against cerebral bleeding in comparison to vitamin K antagonists. Adherence to direct oral anticoagulants resulted in lower risk of stroke and cerebral bleeding. We found no differences in the risk of stroke and gastrointestinal bleeding when we compared direct oral anticoagulants vs. vitamin K antagonists.
Source: Frontiers in Pharmacology - September 15, 2023 Category: Drugs & Pharmacology Source Type: research
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00298-3. doi: 10.1016/S2213-2600(22)00298-3. Online ahead of print.ABSTRACTBACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patient...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Maria Luz Diaz Rafael Diaz Afzalhussein Yusufali Sanjib Kumar Sharma Wadea M Tarhuni Mohamed Hassany Alvaro Avezum Will Source Type: research
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research
